Activating Sphingosine-1-phospahte signaling in endothelial cells increases myosin light chain phosphorylation to...

Area of Science:

• Oncology
• Nanomedicine
• Vascular Biology

Background:

• Metastasis, the spread of cancer, is a major challenge, often involving cancer cells crossing the inflamed vascular endothelium.
• Inflammation increases vascular permeability, creating gaps that facilitate cancer cell dissemination.

Purpose of the Study:

• To develop and evaluate a novel nanoparticle-based therapeutic agent targeting vascular endothelium to inhibit cancer metastasis.
• To investigate the efficacy of nanoASR396, a Sphingosine-1-Phosphate Receptor 1 (S1PR1) agonist, in preventing metastasis.

Main Methods:

• Chemical modification of an S1PR1 agonist (SEW2871) to create ASR396, which was then loaded into nanoliposomes (nanoASR396).
• In vitro studies using microvessels and endothelial cell monolayers to assess nanoASR396's effect on vascular permeability and endothelial cell contractility.
• In vivo studies in animal models to evaluate nanoASR396's efficacy in inhibiting lung metastasis.

Main Results:

• NanoASR396 demonstrated systemic bioavailability upon intravenous injection.
• In vitro, nanoASR396 attenuated inflammatory mediator-induced increases in vascular permeability and inhibited endothelial gap formation by reducing phosphorylated myosin light chain.
• In vivo, nanoASR396 significantly inhibited lung metastasis by up to 80% in animal models.

Conclusions:

• A novel, bioavailable nanoparticle (nanoASR396) activating S1PR1 was successfully developed.
• NanoASR396 effectively counteracts inflammatory effects on the vascular endothelium, inhibiting cancer cell metastasis.
• This nanoparticle-based S1PR1 agonist shows significant potential for preventing melanoma metastasis.